Novo Nordisk A/S (NVO)
132.48
+0.07
(+0.05%)
USD |
NYSE |
May 14, 12:44
Novo Nordisk Debt to Equity Ratio: 0.2722 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | 0.2722 |
December 31, 2023 | 0.1997 |
September 30, 2023 | 0.2854 |
June 30, 2023 | 0.2841 |
March 31, 2023 | 0.3195 |
December 31, 2022 | 0.2546 |
September 30, 2022 | 0.3387 |
June 30, 2022 | 0.3416 |
March 31, 2022 | 0.3829 |
December 31, 2021 | 0.3183 |
September 30, 2021 | 0.208 |
June 30, 2021 | 0.2099 |
March 31, 2021 | 0.1651 |
December 31, 2020 | 0.1056 |
September 30, 2020 | 0.0689 |
June 30, 2020 | 0.069 |
March 31, 2020 | 0.0756 |
December 31, 2019 | 0.0114 |
September 30, 2019 | 0.082 |
June 30, 2019 | 0.0797 |
March 31, 2019 | 0.0913 |
December 31, 2018 | 0.0099 |
September 30, 2018 | 0.0071 |
June 30, 2018 | 0.005 |
March 31, 2018 | 0.0052 |
Date | Value |
---|---|
December 31, 2017 | 0.034 |
September 30, 2017 | 0.0055 |
June 30, 2017 | 0.0347 |
March 31, 2017 | 0.0152 |
December 31, 2016 | 0.0051 |
September 30, 2016 | 0.011 |
June 30, 2016 | 0.0095 |
March 31, 2016 | 0.0109 |
December 31, 2015 | 0.0228 |
September 30, 2015 | 0.0146 |
June 30, 2015 | 0.0188 |
March 31, 2015 | 0.0185 |
December 31, 2014 | 0.0179 |
September 30, 2014 | 0.0075 |
June 30, 2014 | 0.0111 |
March 31, 2014 | 0.0239 |
December 31, 2013 | 0.0051 |
September 30, 2013 | 0.0171 |
June 30, 2013 | 0.0203 |
March 31, 2013 | 0.0089 |
December 31, 2012 | 0.0123 |
September 30, 2012 | 0.0306 |
June 30, 2012 | 0.0284 |
March 31, 2012 | 0.0276 |
December 31, 2011 | 0.0228 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0114
Minimum
Dec 2019
0.3829
Maximum
Mar 2022
0.2036
Average
0.2089
Median
Debt to Equity Ratio Benchmarks
Amgen Inc | 12.75 |
AstraZeneca PLC | 0.8895 |
GSK PLC | 1.284 |
Viking Therapeutics Inc | -- |
Evaxion Biotech AS | -1.825 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 43.24B |
Total Liabilities (Quarterly) | 28.93B |
Shareholders Equity (Quarterly) | 14.31B |
Current Ratio | 0.703 |
Net Debt Paydown Yield | -0.03% |